ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

1,2-Dichloroethane → 2-{4-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-oxo-ethyl]-piperidin-1-yl)-4-trifluoromethyl-benzamide

HRID 1455551
印刷

反応式

HRID 1455551 の反応式
C(Cl)CCl.[C:5]([C:8]1[CH:13]=[CH:12][C:11]([C:14]([F:17])([F:16])[F:15])=[CH:10][C:9]=1[N:18]1[CH2:23][CH2:22][CH:21]([CH2:24][C:25](O)=[O:26])[CH2:20][CH2:19]1)(=[O:7])[NH2:6].[F:28][C:29]([F:45])([F:44])[C:30]1[CH:31]=[C:32]([S:40]([NH2:43])(=[O:42])=[O:41])[CH:33]=[C:34]([C:36]([F:39])([F:38])[F:37])[CH:35]=1.CCN(C(C)C)C(C)C>CN(C1C=CN=CC=1)C.CN(C=O)C>[F:39][C:36]([F:37])([F:38])[C:34]1[CH:33]=[C:32]([S:40]([NH:43][C:25](=[O:26])[CH2:24][CH:21]2[CH2:20][CH2:19][N:18]([C:9]3[CH:10]=[C:11]([C:14]([F:15])([F:17])[F:16])[CH:12]=[CH:13][C:8]=3[C:5]([NH2:6])=[O:7])[CH2:23][CH2:22]2)(=[O:42])=[O:41])[CH:31]=[C:30]([C:29]([F:45])([F:28])[F:44])[CH:35]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 4

HCID 111,2-DichloroethaneHCID 81531DiisopropylethylamineHCID 27831653,5-Bis(trifluoromethyl)benzenesulfonamideHCID 68442763[1-(2-Carbamoyl-5-trifluoromethyl-phenyl)-piperidin-4-yl]-acetic acid

生成物 1

HCID 865970972-{4-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-oxo-ethyl]-piperidin-1-yl)-4-trifluoromethyl-benzamide

試薬・触媒・溶媒

2
HCID 142844-(Dimethylamino)pyridine触媒HCID 6228Dimethylformamide溶媒

実験手順

0.46 g of 2-fluoro-4-(trifluoromethyl)benzamide are added to a suspension of 1.8 g K2CO3 and 0.8 g of piperidin-4-yl acetic acid hydrochloride In 12 ml of DMSO, the mixture obtained is stirred for 4 h at 150°, solvent is evaporated, the evaporation residue obtained is suspended in MeOH and filtrated. The filtrate obtained is concentrated and subjected to chromatography on silica gel. [1-(2-Carbamoyl-5-trifluoromethyl-phenyl)-piperidin-4-yl]-acetic acid is obtained. 300 mg of EDC are added to a solution of 260 mg of [1-(2-carbamoyl-5-trifluoromethyl-phenyl)-piperidin-4-yl]-acetic acid, 230 mg of 3,5-bis-trifluoromethyl-benzenesulfonamide, 200 mg of DIEA and 90 mg of DMAP in 4 ml of DMF. The mixture obtained is stirred for 3 days at RT, solvent is evaporated in vacuo and the evaporation residue obtained is treated with EtAc. The mixture obtained is washed with 1 N HCl, saturated aqueous NaHCO3 solution and brine, dried, concentrated in vacuo and subjected to chromatography on silica gel. 2-{4-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-oxo-ethyl]-piperidin-1-yl}-4-trifluoromethyl-benzamide is obtained.

後処理

  1. customThe mixture obtained
  2. customsolvent is evaporated in vacuo
  3. customthe evaporation residue obtained
  4. additionis treated with EtAc
  5. customThe mixture obtained
  6. washis washed with 1 N HCl, saturated aqueous NaHCO3 solution and brine
  7. customdried
  8. concentrationconcentrated in vacuo

出典と根拠

ORDレコード
ord-332ce80768094c38aa3d78fae640c5f7
出典データセット
uspto-grants-2009_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07482462B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート